Cite
HARVARD Citation
Ottmann, O. et al. (2019). Phase I dose‐escalation trial investigating volasertib as monotherapy or in combination with cytarabine in patients with relapsed/refractory acute myeloid leukaemia. British journal of haematology. pp. 1018-1021. [Online].